Skip to content

The Efficacy of a Minimally Invasive Direct Cochlear Access Via the HEARO Procedure

The Efficacy of a Minimally Invasive Direct Cochlear Access Via the HEARO Procedure

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04102215
Acronym
ARCI25
Enrollment
25
Registered
2019-09-25
Start date
2019-09-01
Completion date
2020-11-04
Last updated
2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sensorineural Hearing Loss

Brief summary

To study the efficacy of a minimally invasive direct cochlear access via the HEARO procedure.

Interventions

DEVICEHEARO

Robotic system for otological procedures

DEVICEOTOPLAN

Otological surgical planning software

Sponsors

Prof. Vedat Topsakal
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

SIngle arm study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Adult cochlear implant candidates with suitable anatomy opting for a MED-EL cochlear implant.

Exclusion criteria

* Age under 18 years * Pregnancy * Distance of the planned trajectory to the facial nerve is \< 0.4mm * Distance of the planned trajectory to the chorda tympani is \< 0.3mm * Vulnerability * Invalid or withdrawn informed consent

Design outcomes

Primary

MeasureTime frameDescription
The relative ratio of the electrode array insertion into the cochlea through the drilled direct cochlea access with HEARO procedure. (Efficacy)Image data aquired during the procedureThe ratio of the number of the procedures in which it was possible to insert the electrode inside the cochlea through the direct cochlear access compared to the number of procedures in which the insertion through the direct cochlea access was not possible will be calculated. Aborted or converted procedures count as procedure in which insertion through the direct cochlea access was not possible. The results will be expressed in relative numbers (n of 25) and in percentage (%).

Secondary

MeasureTime frameDescription
Number of correctlly inserted electrode contact (Efficacy)The procedure (day 0)The number of inserted electrode contacts into the inner ear will be counted in the post-operative image. (Number n) * number of contacts inserted (n)
Insertion depth prediction accuracy (Efficacy)The procedure (day 0)The insertion depth prediction accuracy as the difference between the estimated insertion depth of the electrode at the planning and the actual insertion depth. (Degrees °)
Absolute angular accuracy of the drilled tunnel accessThe procedure (day 0)The absolute in-plane and out-plane accuracy of the drilled tunnel is measured as the angular deviation between the planned and the actual angles.
Electrode array insertion depth (Efficacy)The procedure (day 0)The electrode insertion depth will be measured in the post-operative image. (Degrees °)
Absolute lateral drilling accuracy of the drilled tunnel at the target (Safety)The procedure (day 0)The absolute lateral accuracy of the drilled tunnel is measured as the distance between the planned and actual target position. (mm)
Evaluation of the automatic landmark detection (Performance)The procedure (day 0)The relative ratio of the automatically identified landmarks by OTOPLAN that were not manually adjusted by the surgeon. The intended landmarks are: * Middle ear cavity breakthrough * Bony overhang lateral wall * Bony overhang medial wall The absolute distance between the new position of the adjusted landmark to the position of the automatically identified landmark will be evaluated. (Number n)
Absolute lateral drilling accuracy of the drilled tunnel at the level of facial recess (Safety)The procedure (day 0)The absolute lateral accuracy of the drilled tunnel to the facial nerve and chorda tympani is measured as the difference between the planned and the actual distance. (mm)

Countries

Belgium

Contacts

Primary ContactVedat Topsokal, Prof
vedat.topsakal@uza.be003238213245
Backup ContactPaul Van de Heyning, Prof
Paul.VandeHeyning@uza.be003238213245

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026